Interesting thing is Innovator (AstraZeneca) still has 60% market share despite Teva launching the generic in January, 2015. Torrent management also stated in the concall that its a high volume product and they are targeting high single digit market share. The withdrawal of DRL and Hetero from Nexium market might also result in higher pricing for the near term. Also, it might help in Torrent getting higher market shares and getting inroads in the some of the pharmacy retail chains.
| Subscribe To Our Free Newsletter |
